Webert et al used the Bleeding Severity Measurement Scale (BSMS) to describe bleeding in a patient with chemotherapy-induced thrombocytopenia. The authors are from McMaster University and the Canadian Blood Service.
Groups:
(1) not clinically significant
(2) clinically significant
Clinical Status |
Severity |
Code |
no bleeding at all |
none |
0 |
minimal with no impact on patient, may be detected only by laboratory testing |
trace |
1a |
present but not clinically significant with no impact on patient, does not influence care |
mild |
1b |
any significant bleeding that: (a) causes pain that has to be treated, (b) prompts a therapeutic intervention like blood transfusion or surgery, (c) results in closer monitoring or an invasive study |
serious |
2a |
any significant bleeding that: (a) involves CNS, (b) results in vision loss, (c) causes hemodynamic instability, (d) causes any other morbidity |
serious with moribidity |
2b |
cause of death |
fatal (serious with mortality) |
2c |
Specialty: Hematology Oncology, Clinical Laboratory